

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**SCHEDULE 13G**

Under the Securities Exchange Act of 1934  
(Amendment No. 1)\*

---

**MeiraGTx Holdings plc**  
(Name of Issuer)

**Ordinary Shares, \$0.00003881 par value per share**  
(Title of Class of Securities)

**G59665 102**  
(CUSIP Number)

**August 12, 2024**  
(Date of Event Which Requires Filing of this Statement)

---

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

---

---

1.	Names of Reporting Persons	
	SANOFI	
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) <input type="checkbox"/> (b) <input type="checkbox"/>	
3.	SEC Use Only	
4.	Citizenship or Place of Organization	
	The Republic of France	
Number of Shares Beneficially Owned by Each Reporting Person With	5.	Sole Voting Power 12,197,737 shares
	6.	Shared Voting Power 0 shares
	7.	Sole Dispositive Power 12,197,737 shares
	8.	Shared Dispositive Power 0 shares
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 12,197,737 shares	
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) <input type="checkbox"/>	
11.	Percent of Class Represented by Amount in Row (9) 15.80%	
12.	Type of Reporting Person (See Instructions) CO	

**Item 1.**

- (a) Name of Issuer  
MeiraGTx Holdings plc
- 
- (b) Address of Issuer's Principal Executive Offices  
450 East 29th Street, 14th Floor New York, NY 10016
- 

**Item 2.**

- (a) Name of Person Filing  
Sanofi
- 
- (b) Address of Principal Business Office or, if none, Residence  
46, avenue de la Grande Armée, 75017 Paris, France
- 
- (c) Citizenship  
The Republic of France
- 
- (d) Title of Class of Securities  
Ordinary Shares, \$0.00003881 par value per share
- 
- (e) CUSIP Number  
G59665 102
- 

**Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

- (a)  Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
- (b)  Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c)  Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d)  Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e)  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
- (f)  An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
- (g)  A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
- (h)  A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i)  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j)  A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
- (k)  Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: \_\_\_\_\_

**Item 4. Ownership**

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

- (a) Amount beneficially owned:

12,197,737 shares

---

- (b) Percent of class:

15.80%\*

---

- (c) Number of shares as to which the person has:
- 

- (i) Sole power to vote or to direct the vote

12,197,737 shares

---

- (ii) Shared power to vote or to direct the vote

0 shares

---

- (iii) Sole power to dispose or to direct the disposition of

12,197,737 shares

---

- (iv) Shared power to dispose or to direct the disposition of

0 shares

---

\* Percent based on 77,184,187 ordinary shares outstanding as of August 13, 2024, as disclosed by the Issuer in a prospectus supplement filed by the Issuer with the U.S. Securities and Exchange Commission pursuant to Rule 424(b)(5), which includes the shares issued by the Issuer to two wholly owned subsidiaries of the Reporting Person on August 13, 2024.

**Item 5. Ownership of Five Percent or Less of a Class**

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following .

**Item 6. Ownership of More than Five Percent on Behalf of Another Person**

Sanofi Foreign Participations B.V.	11,500,000 shares	14.90%
Kadmon Corporation, LLC	697,737 shares	0.90%

\* The shares are held of record by Sanofi Foreign Participations B.V. and Kadmon Corporation, LLC, the reporting person's indirect, wholly owned subsidiaries.

**Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person**

The response of the Reporting Person to Item 6 is incorporated herein by reference.

---

**Item 8. Identification and Classification of Members of the Group**

Not applicable.

**Item 9. Notice of Dissolution of Group**

Not applicable.

**Item 10. Certifications**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

**Signature**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

August 13, 2024

\_\_\_\_\_  
Date

/s/ Alexandra Roger\*

\_\_\_\_\_  
Signature

Alexandra Roger  
Head of Legal Corporate & Finance

\_\_\_\_\_  
Name/Title

\* Alexandra Roger is signing on behalf of Sanofi by power of attorney previously filed with the Securities and Exchange Commission on February 3, 2016 as Exhibit 24 to Form 4, and hereby incorporated by reference herein.